X4 Pharmaceuticals Stock Forecast, Price & News

+0.17 (+2.94 %)
(As of 07/29/2021 03:23 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume6,040 shs
Average Volume162,734 shs
Market Capitalization$147.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XFOR News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

X4 Pharmaceuticals logo

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.88 out of 5 stars

Medical Sector

423rd out of 2,214 stocks

Biological Products, Except Diagnostic Industry

62nd out of 213 stocks

Analyst Opinion: 3.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

X4 Pharmaceuticals (NASDAQ:XFOR) Frequently Asked Questions

Is X4 Pharmaceuticals a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" X4 Pharmaceuticals stock.
View analyst ratings for X4 Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than X4 Pharmaceuticals?

Wall Street analysts have given X4 Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but X4 Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting X4 Pharmaceuticals?

X4 Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 590,400 shares, an increase of 61.7% from the June 30th total of 365,100 shares. Based on an average daily volume of 225,800 shares, the days-to-cover ratio is presently 2.6 days. Currently, 2.9% of the company's stock are short sold.
View X4 Pharmaceuticals' Short Interest

When is X4 Pharmaceuticals' next earnings date?

X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for X4 Pharmaceuticals

How can I listen to X4 Pharmaceuticals' earnings call?

X4 Pharmaceuticals will be holding an earnings conference call on Tuesday, August 3rd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its quarterly earnings data on Thursday, May, 6th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.46.
View X4 Pharmaceuticals' earnings history

How has X4 Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

X4 Pharmaceuticals' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XFOR stock has decreased by 30.0% and is now trading at $6.01.
View which stocks have been most impacted by COVID-19

What price target have analysts set for XFOR?

6 brokers have issued 1-year price objectives for X4 Pharmaceuticals' stock. Their forecasts range from $15.00 to $27.00. On average, they expect X4 Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 232.8% from the stock's current price.
View analysts' price targets for X4 Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are X4 Pharmaceuticals' key executives?

X4 Pharmaceuticals' management team includes the following people:
  • Dr. Paula Ragan, Founder, CEO, Pres, Sec. & Director (Age 51, Pay $551.57k)
  • Mr. Adam S. Mostafa, CFO, Treasurer & Assistant Sec. (Age 41, Pay $400.56k)
  • Mr. Derek M. Meisner Esq., J.D., Gen. Counsel (Age 50, Pay $479.46k)
  • Dr. Mary DiBiase, Sr. VP of Technical Operations & Quality
  • Dr. Arthur Taveras, Chief Scientific Officer
  • Ms. Candice Ellis, Director of Corp. Communications & Investor Relations
  • Ms. Ronny Mosston, Sr. VP of HR
  • Dr. Robert David Arbeit, Sr. VP of Clinical Devel. and Translational Research (Age 73)
  • Ms. Carrie Melvin M.B.A., Sr. VP of Devel. Operations
  • Dr. Diego Cadavid M.D., Chief Medical Officer (Age 55)

Who are some of X4 Pharmaceuticals' key competitors?

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

What is X4 Pharmaceuticals' stock symbol?

X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR."

Who are X4 Pharmaceuticals' major shareholders?

X4 Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Minot Wealth Management LLC (0.07%). Company insiders that own X4 Pharmaceuticals stock include Adam S Mostafa, Derek M Meisner, Paula Ragan and Renato Skerlj.
View institutional ownership trends for X4 Pharmaceuticals

Which major investors are buying X4 Pharmaceuticals stock?

XFOR stock was purchased by a variety of institutional investors in the last quarter, including Minot Wealth Management LLC.
View insider buying and selling activity for X4 Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is X4 Pharmaceuticals' stock price today?

One share of XFOR stock can currently be purchased for approximately $6.01.

How much money does X4 Pharmaceuticals make?

X4 Pharmaceuticals has a market capitalization of $148.85 million and generates $3 million in revenue each year. The company earns $-62,130,000.00 in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does X4 Pharmaceuticals have?

X4 Pharmaceuticals employs 75 workers across the globe.

What is X4 Pharmaceuticals' official website?

The official website for X4 Pharmaceuticals is

Where are X4 Pharmaceuticals' headquarters?

X4 Pharmaceuticals is headquartered at 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139.

How can I contact X4 Pharmaceuticals?

X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-529-8300 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.